The changes of serum CXCL-12 levels in patients with septic shock and its influence for prognosis
YU Shanling1 LIU fengsui1 XU Shufeng2 LIU Feifei2
1.the Second Department of Critical Care Medicine, Qinhuangdao First Hospital, Hebei Province, Qinhuangdao 066000, China;
2.the First Department of Respiration, Qinhuangdao First Hospital, Hebei Province, Qinhuangdao 066000, China
Abstract：Objective To study the changes of serum CXCL-12 levels in patients with septic shock and its influence for prognosis. Methods From August 2016 to May 2017, 97 cases of septic shock patients treated in Qinhuangdao First Hospital were selected, including 79 cases of survivors and 18 cases of death. According to whether or not there were multiple organ functional disorder, they were divided into 34 patients with multiple organ functional disorder group (DF group) and 63 patients without multiple organ functional disorder group (NDF group). Over the same period, 40 healthy volunteers were selected as the control group. Serum CXCL-12 levels were detected, serum CXCL-12 and APACHEⅡ scores in different prognosis of patients were compared, influence factors of death were analyzed. Results The levels of serum CXCL-12 in DF group and NDF group were significantly higher than that of control group, and the level of serum CXCL-12 and the score of APACHEⅡ in the DF group were significantly higher than those in the NDF group, with statistically significant differences (P ＜ 0.05). The level of serum CXCL-12 and the score of APACHEⅡ in the survival group were significantly lower than those of the death group (P ＜ 0.05). The Logistic regression analysis showed that the influence factors of death in patients after treatment were CXCL-12 and APACHEⅡ score (P ＜ 0.05). Conclusion The level of serum CXCL-12 in patients with septic shock is significantly higher and continues to rise with the deterioration of illness and prognosis. CXCL-12 and APACHEⅡ score are the independent risk factors of death of patients with septic shock. The change of CXCL-12 level in patients with septic shock should be strictly monitored, the APACHEⅡ score should evaluated timely. Thus, the prognosis of patients with septic shock can be evaluated more scientifically and accurately
于珊玲1 刘丰遂1 徐淑凤2 刘菲菲2. 感染性休克患者血清CXCL-12水平变化及其对预后的影响[J]. 中国医药导报, 2018, 15(4): 65-68.
YU Shanling1 LIU fengsui1 XU Shufeng2 LIU Feifei2. The changes of serum CXCL-12 levels in patients with septic shock and its influence for prognosis. 中国医药导报, 2018, 15(4): 65-68.
[1] 方向明，易高，王志敏，等.乌司他丁联合阿托莫兰对感染性休克患者血清IL-6，TNF-α和PCT水平的影响[J].现代生物医学进展，2017，17（3）：496-499.
[2] 苗楠，皮秀梅，克依木，等.ICU感染性休克病死危险因素及相应的临床治疗措施分析[J].中国现代药物应用，2016，10（9）：52-53.
[3] 王咸安，陈梁，王玉花，等.生脉注射液联合乌司他丁治疗感染性休克的临床研究[J].现代药物与临床，2017，32（2）：249-252.
[4] Fernando R，Atkins SJ，Smith TJ，et al. Intersection of Che?鄄mokine and TSH Receptor Pathways in Human Fibrocytes：Emergence of CXCL-12/CXCR4 Cross Talk Potenti?鄄ally Relevant to Thyroid-Associated Ophthalmopathy [J]. Endocrinology，2016，157（10）：3779-3787.
[5] 辛琪，张勤，张娜，等.趋化因子配体12、趋化因子受体7在肠型胃癌中的表达与淋巴结和肝脏转移的关系[J].中华消化杂志，2016，36（11）：740-745.
[6] Singer J，Testori C，Schellongowski P，et al. A case report of septic shock syndrome caused by S. pneumoniae in an immunocompromised patient despite of vaccination [J]. BMC Infect Dis，2017，17（1）：442-444.
[7] 北京市科委重大项目“MODS中西医结合诊治/降低病死率研究”课题组.多器官功能障碍综合征诊断标准、病情严重度评分及预后评估系统和中西医结合证型诊断[J].中国危重病急救医学，2008，20（1）：1-2.
[8] Tavakolian FV，Mohammadi M，Hassanshahi G，et al. Serum CXCL10 and CXCL12 chemokine levels are associated with the severity of coronary artery disease and coronary artery occlusion [J]. Int J Cardiol，2017，15（233）：23-28.
[9] 于转转，郗彦凤，李静，等.CXCL12/CXCR4与T淋巴母细胞淋巴瘤/白血病预后的相关性[J].中华病理学杂志，2016，45（12）：838-843.
[10] Keeley A，Hine P，Nsutebu E，et al. The recognition and management of sepsis and septic shock：a guide for non-intensivists [J]. Postgrad Med J，2017，93（1104）：626-634.
[11] 连向阳，古纪欢，王金宝，等.急腹症合并感染性休克死亡因素的Logistic回归分析[J].中国实用医药，2017，12（7）：94-96.
[12] Lin WC，Chen CW，Chao L，et al. Plasma kallistatin in critically ill patients with severe sepsis and septic shock [J]. PLoS One，2017，12（5）：178 387-178 388.
[13] 巫亚颖，孟浩，杨林军，等.血清CXCL-12对感染性休克患者预后的评估价值[J].贵州医科大学学报，2017， 42（8）：974-978.
[14] 张扬，冯勇，商瑜，等.不同麻醉方式对急腹症感染性休克患者血流动力学和炎症应激反应及免疫功能的影响[J].医药导报，2017，36（5）：520-523.
[15] 熊书君.肝癌患者血清趋化因子12和IL-6水平与其转移复发的关系[J].实用癌症杂志，2017，32（1）：27-29.
[16] 郭文龙，周源，彭祝军，等.外科ICU感染性休克病死危险因素及相应的临床治疗措施探讨[J].泰山医学院学报，2017，38（4）：410-411.
[17] Chatterjee K，Goyal A，Chada A，et al. National Trends（2007-2013）of Clostridium difficile Infection in Patients with Septic Shock：Impact on Outcome [J]. J Hosp Med，2017，12（9）：717-722.
[18] 杨俊波，黄晓洁.白细胞介素-24通过CXC趋化因子配体12/CXC趋化因子受体4信号轴抑制肿瘤细胞转移[J].中华实验外科杂志，2015，32（10）：2465-2468.
[19] Hamed S，Behnes M，Pauly D，et al. Diagnostic value of Pentraxin-3 in patients with sepsis and septic shock in accordance with latest sepsis-3 definitions [J]. BMC Infect Dis，2017，17（1）：554-555.
[20] 潘田君，杨玲飞.多巴胺联合去甲肾上腺素对重症感染性休克患者血乳酸、炎性因子的影响[J].中国基层医药，2017，24（16）：2520-2524.
2018, Vol. 15 
京公网安备 11010502046598号